- Clinical Trial Protocol for HyNOVA: Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020)
-
Farrell R, Burling M, Lee YC, Pather S, Robledo K, Mercieca-Bebber R, Stockler M, on behalf of the HyNOVA Protocol Steering Committee
- KMID: 2536007
- J Gynecol Oncol.
- 2022 Jan;33(1):e1.
- doi: 10.3802/jgo.2022.33.e1
Background Ovarian cancer is the most lethal gynecological cancer, causing over 200,000 deaths worldwide in 2020. Initial standard treatment for primary ovarian cancer is optimal cytoreductive surgery (CRS) preceded and/or followed... -
- CITED
-
- Close
- SHARE
-
- Close
- Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study
-
Blinman P, Gainford C, Donoghoe M, Martyn J, Blomfield , Grant P, Kichenadasse G, Vaughan M, Brand A, Shannon C, Gebski V, Stockler M, Friedlander M
- KMID: 2177878
- J Gynecol Oncol.
- 2013 Oct;24(4):359-366.
- doi: 10.3802/jgo.2013.24.4.359
OBJECTIVE: Intraperitoneal (IP) chemotherapy in women with optimally debulked stage III ovarian cancer has been reported to prolong overall survival, but has not been widely adopted due to concerns about... -
- CITED
-
- Close
- SHARE
-
- Close
